Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MITF | O75030 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16056837 | 0.77 | CYP2A6 (0.43) | KDM4EMAPTHTTCYP2A6HSP90AA1 | |
| SCHEMBL4135470 | 0.73 | HSD17B10 (0.40) | KDM4EMITFMAPTHTTHSP90AA1 | |
| SCHEMBL2129184 | 0.70 | HSD17B10 (0.46) | KDM4EMAPTHTTHSD17B10SMN1; SMN2 | |
| SCHEMBL16056949 | 0.68 | ATM (0.48) | MAPTHTTATMHSD17B10SMN1; SMN2 | |
| SCHEMBL10396004 | 0.67 | CYP3A4 (0.59) | KDM4EMAPTHSP90AA1NPC1RAB9A | |
| SCHEMBL8363005 | 0.65 | NPC1 (0.60) | KDM4EMAPTHTTNPC1RAB9A | |
| SCHEMBL10394650 | 0.65 | L3MBTL1 (0.62) | KDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20379640 | 0.65 | TSHR (0.64) | KDM4EMAPTHTTSMN1; SMN2 | |
| SCHEMBL29038792 | 0.63 | HSP90AA1 (0.60) | KDM4EMAPTHTTCYP2A6HSP90AA1 | |
| SCHEMBL10975798 | 0.63 | HTT (0.33) | KDM4EMITFMAPTHTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9797883-B2 | Re-trafficking of herg reverses long QT syndrome 2 phenotype in human iPS-derived cardiomyocytes | SINGAPORE HEALTH SERVICES PTE LTD (SG) | 2017-10-24 | — | — | US | claimed |
| EP-2972323-B1 | RE-TRAFFICKING OF HERG REVERSES LONG QT SYNDROME 2 PHENOTYPE IN HUMAN IPS-DERIVED CARDIOMYOCYTES | SINGAPORE HEALTH SERV PTE LTD (SG) | 2017-09-13 | — | — | EP | claimed |
| US-20160033481-A1 | RE-TRAFFICKING OF HERG REVERSES LONG QT SYNDROME 2 PHENOTYPE IN HUMAN IPS-DERIVED CARDIOMYOCYTES | SINGAPORE HEALTH SERVICES PTE LTD (SG) | 2016-02-04 | — | — | US | claimed |
| EP-2972323-A2 | RE-TRAFFICKING OF HERG REVERSES LONG QT SYNDROME 2 PHENOTYPE IN HUMAN IPS-DERIVED CARDIOMYOCYTES | Singapore Health Services Pte Ltd (SG) | 2016-01-20 | — | — | EP | claimed |
| WO-2014142760-A2 | RE-TRAFFICKING OF HERG REVERSES LONG QT SYNDROME 2 PHENOTYPE IN HUMAN IPS-DERIVED CARDIOMYOCYTES | SINGAPORE HEALTH SERVICES PTE LTD (SG) | 2014-09-18 | — | — | WO | claimed |
| US-12590966-B2 | Method for treating cancer | THE CHILDREN'S MEDICAL CENTER CORPORATION | 2026-03-31 | — | — | US | disclosed |
| US-20230149295-A1 | INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO | UNIVERSITY OF HOUSTON SYSTEM (US) | 2023-05-18 | — | — | US | disclosed |
| EP-4121111-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY AND FIBROTIC PULMONARY DISORDERS | University of Houston System (US) | 2023-01-25 | — | — | EP | disclosed |
| EP-4117718-A1 | INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO | University of Houston System (US) | 2023-01-18 | — | — | EP | disclosed |
| US-20230003732-A1 | METHOD FOR TREATING CANCER | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-01-05 | — | — | US | disclosed |
| EP-3359196-B1 | RATIONAL COMBINATION THERAPY FOR THE TREATMENT OF CANCER | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-03-16 | — | — | EP | disclosed |
| US-20210401987-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY AND FIBROTIC PULMONARY DISORDERS | UNIVERSITY OF HOUSTON SYSTEM (US) | 2021-12-30 | — | — | US | disclosed |
| EP-2467142-B1 | 2-(Pyrimidin-5-yl)-thiopyrimidine derivatives as Hsp70 and Hsc70 modulators for the treatment of proliferative disorders | SLOAN KETTERING INST CANCER (US) | 2016-09-21 | — | — | EP | disclosed |
| EP-2467142-B1 | 2-(Pyrimidin-5-yl)-thiopyrimidine derivatives as Hsp70 and Hsc70 modulators for the treatment of proliferative disorders | SLOAN KETTERING INST CANCER (US) | 2016-09-21 | — | — | EP | disclosed |
| US-20160033481-A1 | RE-TRAFFICKING OF HERG REVERSES LONG QT SYNDROME 2 PHENOTYPE IN HUMAN IPS-DERIVED CARDIOMYOCYTES | SINGAPORE HEALTH SERVICES PTE LTD (SG) | 2016-02-04 | — | — | US | disclosed |
| EP-2972323-A2 | RE-TRAFFICKING OF HERG REVERSES LONG QT SYNDROME 2 PHENOTYPE IN HUMAN IPS-DERIVED CARDIOMYOCYTES | Singapore Health Services Pte Ltd (SG) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014142760-A2 | RE-TRAFFICKING OF HERG REVERSES LONG QT SYNDROME 2 PHENOTYPE IN HUMAN IPS-DERIVED CARDIOMYOCYTES | SINGAPORE HEALTH SERVICES PTE LTD (SG) | 2014-09-18 | — | — | WO | disclosed |
| US-20120252818-A1 | HEAT SHOCK PROTEIN BINDING COMPOUNDS, COMPOSITIONS, AND METHODS FOR MAKING AND USING SAME | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2012-10-04 | — | — | US | disclosed |
| EP-2467142-A2 | HEAT SHOCK PROTEIN BINDING COMPOUNDS, COMPOSITIONS, AND METHODS FOR MAKING AND USING SAME | Memorial Sloan-Kettering Cancer Center (US) | 2012-06-27 | — | — | EP | disclosed |
| WO-2011022440-A2 | HEAT SHOCK PROTEIN BINDING COMPOUNDS, COMPOSITIONS, AND METHODS FOR MAKING AND USING SAME | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210401987-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY AND FIBROTIC PULMONARY DISORDERS | MMP1, MMP8, CCL11 | KDM4E 3729/4885MITF 4209/4885MAPT 3332/4885 |
| US-20230003732-A1 | METHOD FOR TREATING CANCER | GSK3A, GSK3B, GSKIP | KDM4E 3029/4885MITF 4045/4885MAPT 1728/4885 |
| US-20120252818-A1 | HEAT SHOCK PROTEIN BINDING COMPOUNDS, COMPOSITIONS, AND METHODS FOR MAKING AND USING SAME | HSPBP1, HSF1, HSPA2 | KDM4E 3776/4885MITF 2126/4885MAPT 606/4885 |
| US-20230149295-A1 | INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO | EPCAM, FABP2, TPMT | KDM4E 448/4885MITF 1936/4885MAPT 4173/4885 |
| US-12590966-B2 | Method for treating cancer | GSK3B, GSK3A, GSKIP | KDM4E 3160/4885MITF 4036/4885MAPT 1305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.